Daily Sepsis Research Analysis
Analyzed 26 papers and selected 3 impactful papers.
Summary
Analyzed 26 papers and selected 3 impactful articles.
Selected Articles
1. Restrictive Versus Liberal Fluid Strategy for Initial Resuscitation in Sepsis and Septic Shock: A Systematic Review and Meta Analysis.
Across 15 studies (5,013 adults), restrictive fluid strategies did not change all-cause mortality compared with liberal/standard care but were associated with reduced AKI, ARDS, and mechanical ventilation dependence. Trial sequential analysis indicated mortality evidence remains inconclusive, underscoring the need for adequately powered trials.
Impact: This synthesis clarifies that restrictive fluid resuscitation may protect organs without improving mortality, guiding nuanced fluid strategies in early sepsis care. It sets the agenda for future large RCTs focusing on patient-centered and organ outcomes.
Clinical Implications: Clinicians can consider restrictive, physiology-guided fluids to potentially lower AKI/ARDS risk while recognizing no proven mortality benefit; hemodynamic monitoring and early vasopressors may be prioritized over liberal fluid loading.
Key Findings
- Restrictive fluid strategy showed no significant mortality difference versus liberal/standard care in RCTs (RR ~0.99, 95% CI 0.90–1.08).
- Restrictive fluids were associated with lower risks of AKI and ARDS and reduced dependence on mechanical ventilation.
- Trial sequential analysis indicated mortality evidence remains inconclusive, requiring larger trials.
Methodological Strengths
- PRISMA/MOOSE-compliant systematic search and selection with nine RCTs included.
- Use of random-effects models and trial sequential analysis to assess conclusiveness.
Limitations
- Heterogeneity in fluid protocols and co-interventions across studies.
- Mortality effects remain underpowered; mixture of RCTs and observational studies may introduce bias.
Future Directions: Large, protocol-harmonized RCTs incorporating dynamic perfusion targets and early vasopressor use should test patient-centered outcomes beyond mortality, including AKI, ARDS, and quality of life.
BACKGROUND: Intravenous fluid resuscitation is essential in early management of sepsis, but the optimal volume and resuscitation strategy are uncertain. This systematic review and meta-analysis aimed to synthesize the evidence comparing the efficacy and safety of restrictive versus liberal fluid resuscitation strategies in adults with sepsis or septic shock. METHODS: A systematic search of PubMed, Web of Science (WoS), Scopus, and CENTRAL was conducted from inception to November 2025, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Randomized controlled trials (RCTs) and observational cohort studies comparing protocolized restrictive fluid strategies with liberal or standard care were included. Primary outcomes were all-cause mortality and acute kidney injury (AKI). Random-effects models were used to calculate pooled risk ratios (RRs) and mean differences (MDs), while trial sequential analysis (TSA) assessed the conclusiveness of evidence. RESULTS: Sixteen reports from 15 unique studies (nine RCTs and six observational studies) involving 5,013 patients were included. In the analysis of RCTs, restrictive fluid therapy resulted in no significant difference in all-cause mortality (RR = 0.99; 95% CI, 0.90-1.08; I CONCLUSIONS: Restrictive fluid resuscitation does not reduce overall mortality in adults with sepsis or septic shock, but it is associated with lower AKI and ARDS risk and decreased dependence on mechanical ventilation. Evidence regarding mortality is inconclusive, highlighting the need for large-scale trials to validate this finding.
2. The cellular response capacity (CRC) as a novel immunomonitoring approach in sepsis.
CRC, a standardized flow cytometry-derived metric, detected systemic inflammation at lower pathogen burdens than IL-6 in an experimental bacteremia model and discriminated clinical sepsis from controls, with CD11b-CRC performing best. The maximal stimulation reference point was stable across instruments and inflammatory states, and CRC tracked postoperative inflammation more precisely than conventional biomarkers.
Impact: Introduces a robust, standardized cell-based biomarker that can enable earlier and more precise sepsis diagnosis than humoral markers. The approach addresses a key translational gap: reproducible flow cytometry for clinical immunomonitoring.
Clinical Implications: CRC could be integrated into ED or ICU workflows to expedite sepsis recognition and monitor immune recovery, potentially informing antimicrobial initiation, de-escalation, and immunomodulatory strategies once validated prospectively.
Key Findings
- CRC (CD10, CD11b, CD66b) increased dose-dependently with bacterial burden and outperformed IL-6 at low pathogen loads.
- In clinical sepsis cohorts, CRC discriminated patients from matched healthy controls; CD11b-CRC showed highest diagnostic performance.
- The maximal stimulation reference point was stable across inflammatory states, cohorts, and instruments, supporting standardization.
- CRC captured onset/resolution of surgery-induced inflammation more precisely than conventional biomarkers.
Methodological Strengths
- Combines an experimental bacteremia model with clinical cohort validation.
- Establishes a stable maximal stimulation reference enabling cross-instrument standardization.
Limitations
- Sample size and multicenter external validation details are not specified in the abstract.
- Clinical outcome impact (e.g., time-to-antibiotics, mortality) not yet demonstrated.
Future Directions: Prospective, multicenter diagnostic accuracy and impact studies should evaluate CRC-triggered care pathways on time-to-antibiotics, ICU admission, and mortality; assay automation and quality control standards are needed for widespread adoption.
BACKGROUND: Early recognition of sepsis remains difficult in clinical practice because conventional humoral biomarkers such as C-reactive protein, procalcitonin, and interleukin-6 (IL-6) exhibit unfavorable, slow-release kinetics and rise hours after the onset of infection. Flow cytometry enables upstream, cell-based immunomonitoring, but its clinical use is restricted by poor standardization of fluorescence measurements. In this study, the neutrophil cellular response capacity (CRC) was developed and evaluated as a standardized approach for rapid assessment of systemic inflammation in bacteremia and sepsis. METHODS: The CRC is based on a flow cytometry-based framework that defines a stable maximal stimulation reference point for neutrophil granulocytes. The CRC was evaluated in a human RESULTS: In the bacteremia model, the CRC of neutrophil markers CD10, CD11b, and CD66b increased in a dose-dependent manner with increasing bacterial burden and detected inflammation at lower pathogen burdens than IL-6 and other humoral mediators, with a superior area under the receiver operating characteristic curve. In clinical sepsis, the CRC discriminated patients from age- and sex-matched healthy volunteers, with the CRC of CD11b showing the highest diagnostic performance. CRC values increased over time in patients with sepsis, consistent with immunological recovery. The maximal stimulation reference point for CD11b remained stable across inflammatory states, cohorts, and instruments. In addition, the CRC more precisely captured the onset and resolution of surgery-induced inflammation than conventional biomarkers. CONCLUSIONS: The CRC provides a rapid, standardized, and robust cell-based immunomonitoring tool that outperforms traditional humoral markers in experimental bacteremia and reliably identifies sepsis in clinical cohorts, strongly supporting its use as a novel biomarker for earlier, more precise sepsis diagnosis and monitoring.
3. Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort.
In 2,394 E. coli BSI cases across 26 hospitals, ESBL producers had higher crude 30-day mortality but the association disappeared after adjusting for baseline factors and appropriate empiric therapy using multiple propensity score approaches. The findings underscore that delayed/inappropriate empiric therapy, not ESBL status per se, likely drives excess mortality.
Impact: Resolves a long-standing controversy by rigorously addressing confounding: ESBL production is not independently associated with higher mortality when empiric therapy is appropriate. This informs stewardship and empiric coverage decisions.
Clinical Implications: For suspected E. coli BSI, risk stratification should prioritize timely appropriate empiric coverage in high-risk patients, while recognizing ESBL status alone does not worsen prognosis when therapy is adequate; de-escalation is advisable once susceptibilities return.
Key Findings
- Among 2,394 E. coli BSIs, 13.5% were ESBL-producing; appropriate empiric therapy occurred in 53.7% vs 92.0% for ESBL vs non-ESBL.
- Crude 30-day mortality was higher for ESBL (14.6% vs 9.6%; OR 1.61), but after PS adjustment and accounting for appropriate therapy, the OR was 1.12 (95% CI 0.75–1.67).
- Multiple propensity score applications (covariate, matching, IPTW, stratification) yielded consistent non-significant adjusted associations.
Methodological Strengths
- Prospective, multicenter cohort with large sample size across 26 hospitals.
- Robust confounding control using multiple propensity score methods and adjustment for appropriateness of empiric therapy.
Limitations
- Observational design cannot fully eliminate residual confounding.
- Generalizability may be limited to similar healthcare settings; therapeutic practices may vary across regions.
Future Directions: Investigate optimized empiric regimens guided by risk scores and rapid diagnostics to minimize inappropriate therapy; assess patient-centered outcomes and cost-effectiveness of targeted coverage strategies.
OBJECTIVE: The incidence of bloodstream infection (BSIs) due to extended-spectrum β-lactamase (ESBL) producing Escherichia coli is increasing worldwide. There is controversy as to whether ESBL production in itself is associated with higher mortality. The aim of this study is to evaluate the impact of ESBL production on mortality in BSIs due to E. coli considering the effect of confounders. METHODS: PROBAC study is a prospective, multicentre, cohort study performed in 26 Spanish hospitals (October 2016-March 2017). All patients with E. coli BSIs were included. The outcome variable was all-cause 30-day mortality. Confounding was controlled by calculating a propensity score (PS) for ESBL production using baseline variables. PS were used as covariable, for matching, for inverse probability of treatment weight analysis and for stratified analysis within the PS quartiles. RESULTS: A total of 2394 cases were included, of which 322 (13.5%) were ESBL-producing isolates. The frequency of appropriate empirical treatment, in ESBL-producing and non-ESBL-producing isolates, was 53.7% and 92.0%, respectively. Thirty-day mortality was 14.6% in ESBL-producing isolates versus 9.6% in non-ESBL-producing isolates (P = 0.006), for a crude OR of 1.61 (95% CI: 1.14-2.27; P = 0.006). When we adjusted by PS and appropriate empirical treatment, the OR changed to 1.12 (95% CI: 0.75-1.67; P = 0.584). Other PS applications provided similar results. CONCLUSION: BSIs due to ESBL-producing E. coli were associated with higher mortality in the crude analyses; however, the estimate of the association is reduced after adjustment for baseline variables and empirical therapy, and is not significant in matched analysis.